GSK signs shingles vaccine deal with China’s Zhifei for around $3 bln, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

The deal is one of a series of moves by western pharmaceutical firms to seize a bigger share of China’s market, including announcements from companies such as AstraZeneca. The vaccine, named Shingrix, is GSK’s top-selling medicine. The deal with Zhifei is part of its efforts to reach more than 4 billion pounds ($4.88 billion) in sales by 2026., The deal is one of a series of moves by western pharmaceutical firms to seize a bigger share of China’s market, including announcements from companies such as AstraZeneca. The vaccine, named Shingrix, is GSK’s top-selling medicine. The deal with Zhifei is part of its efforts to reach more than 4 billion pounds ($4.88 billion) in sales by 2026., , Read More